Skip to content
PeptideAgent

Compounding pharmacies in North Carolina

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

The North Carolina Board of Pharmacy regulates compounding pharmacies in North Carolina. Compounded GLP-1 limited. How to check a pharmacy's license, plus verified listings.

North Carolina at a glance

503A framework
Follows the federal 503A framework
Telehealth prescribing
Regulatory: Telehealth allowed
Asynchronous prescribing
Regulatory: Async unclear
Compounded GLP-1 access
Regulatory: Compounded GLP-1 limited

Verified compounding pharmacies serving North Carolina

No verified compounding pharmacies serving North Carolina are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.

Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.

Run a pharmacy, clinic, or telehealth service? Apply for a listing.

Who regulates compounding pharmacies in North Carolina

The Board of Pharmacy issues pharmacy permits under the North Carolina Pharmacy Practice Act (G.S. Chapter 90, Article 4A) and adopts rules in 21 NCAC 46, including the compounding rule in Section .2800. Under G.S. 90-85.21A, any pharmacy outside North Carolina that ships, mails, or delivers dispensed legend drugs into the state must register with the Board every year, and the Board may deny registration to a pharmacy disciplined in its home state for compounding or dispensing violations that threaten public health. The Board's July 2023 newsletter (Vol. 45, No. 1, Item 2465, "Statement Concerning Semaglutide Compounding") announced a Board staff guidance document on when federal law permits compounding a copy of a commercially available drug and how that applies to semaglutide; the Board's general pharmacy FAQ says the statement was updated after FDA's April 2023 clarification of semaglutide's shortage status, but the linked statement itself could not be retrieved from the Board's site when this record was checked, so its specific terms are not summarized here. The same FAQ now says FDA found semaglutide injection shortages resolved and would not act against state-licensed 503A pharmacies only until April 22, 2025, and that compounding copies of approved tirzepatide products is no longer allowed. North Carolina has no state bulks list; peptide eligibility follows the federal 503A framework. [1] [2] [3] [4] [5] [7]

Compounded GLP-1 access in North Carolina

Any out-of-state pharmacy shipping compounded GLP-1s in must hold an annual G.S. 90-85.21A registration. [2] [4] [10]

Research use only sellers in North Carolina

The North Carolina Food, Drug, and Cosmetic Act (G.S. 106-120 and following) prohibits selling adulterated or misbranded drugs, and the Pharmacy Practice Act restricts dispensing of legend drugs to permitted pharmacies. [3] [6] [11]

North Carolina notes on specific peptides

  • Semaglutide: Available branded by prescription, including by telemedicine from a North Carolina-licensed prescriber. Compounded semaglutide is limited to the federal patient specific exception since April 22, 2025, the date the North Carolina Board of Pharmacy's FAQ gives for the end of FDA's grace period for 503A pharmacies. [5] [10]

How to check a compounding pharmacy in North Carolina

  1. Search the North Carolina Board of Pharmacy license lookup for the pharmacy by name. A pharmacy based elsewhere needs whatever license or registration North Carolina requires before it ships to you. [1] [2] [3] [4] [5] [7]
  2. Ask whether it operates as a 503A pharmacy or a 503B outsourcing facility, and confirm a 503B claim against FDA's outsourcing facility information (see the verification checklist).
  3. Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
  4. Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in North Carolina. [3] [6] [11]

Common questions in North Carolina

Can an out-of-state pharmacy ship compounded peptides to me in North Carolina?

Only if it registers annually with the North Carolina Board of Pharmacy under G.S. 90-85.21A. The Board can refuse registration to pharmacies disciplined at home for compounding violations. [1] [2]

What has the North Carolina Board of Pharmacy said about compounded semaglutide?

In 2023 Board staff issued a guidance statement on if, when, and how semaglutide may be compounded, announced in the Board's July 2023 newsletter. The Board's current FAQ says FDA found semaglutide injection shortages resolved and stopped extending enforcement discretion to 503A pharmacies after April 22, 2025, and that compounding copies of approved tirzepatide products is no longer allowed. [4] [5]

Can a North Carolina pharmacy compound BPC-157?

No, not from bulk today. BPC-157 is not on the 503A bulks list. PCAC's July 2026 recommendation is advisory, and until FDA publishes a final rule a 503A pharmacy has no federal basis to compound it from bulk. State boards cannot authorize what federal law does not. Peptides still in FDA Category 2 cannot be compounded either. [7] [8] [9]

All peptide legal questions for North Carolina

Sources

  1. [1]North Carolina Board of Pharmacy
  2. [2]N.C. G.S. 90-85.21A, Pharmacies outside North Carolina (nonresident registration)
  3. [3]N.C. G.S. Chapter 90, Article 4A, North Carolina Pharmacy Practice Act
  4. [4]North Carolina Board of Pharmacy newsletter, July 2023 (semaglutide compounding)
  5. [5]North Carolina Board of Pharmacy: General pharmacy FAQs (compounding GLP-1s and semaglutide)
  6. [6]N.C. G.S. Chapter 106, Article 12, Food, Drug, and Cosmetic Act
  7. [7]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
  8. [8]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B category lists)FDA
  9. [9]FDA: Pharmacy Compounding Advisory CommitteeFDA
  10. [10]FDA: concerns with unapproved GLP-1 drugs used for weight loss, including shortage resolution and compounding grace periodsFDA
  11. [11]21 U.S.C. 331, Prohibited acts